Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

NASDAQ:LGND   3:59:59 PM EDT
134.96
-0.90 (-0.66%)
Products, Regulatory

Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results From The Ongoing Phase 3 Protect Study Of Sparsentan In Iga Nephropathy

Published: 08/16/2021 18:58 GMT
Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B (LGND) - Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results From the Ongoing Phase 3 Protect Study of Sparsentan in Iga Nephropathy.
Ligand Pharmaceuticals Inc - Sparsentan Has Been Generally Well-tolerated and Consistent With Previously Observed Safety Profile to Date.
Ligand Pharmaceuticals - Sparsentan Treatment Demonstrated a Statistically Significant Mean Reduction of Proteinuria From Baseline After 36 Weeks.
Ligand Pharmaceuticals Inc - Travere Plans to Submit an Application for Accelerated Approval in U.S. in First Half of 2022.
Ligand Pharmaceuticals - Travere Also Plans to Submit an Application for Conditional Marketing Authorization in Europe.